Dr. Hans-Peter Vornlocher,

Managing Director Research

Hans-Peter studied Biology at the University Erlangen, Germany, and after obtaining his Ph.D. in Biochemistry from the University Bayreuth, Germany, he held a postdoctoral position at the University of California in Davis, CA, for three years. Prior to joining Ribopharma AG as Head of Biochemistry in 2001, Hans-Peter worked as a Senior Scientist in Prof. Lührmann's departments at the Institute for Molecular Biology and Tumor Research in Marburg and at the Max-Planck-Institute for Biophysical Chemistry in Göttingen, Germany. At Alnylam Europe AG Hans-Peter served as VP Research and Managing Director Research, a position he also held at Roche Kulmbach GmbH. Hans-Peter has more than 20 years experience in the field of RNA research. He has published more than 45 peer reviewed articles, reviews and book chapters and is inventor on more than 30 patents.

Andreas Bossko,

Managing Director Finance

Andreas is a qualified master of business administration with a diploma from the University Bayreuth, Germany. In addition to his economic education he has a comprehensive knowledge from his preceding studies in molecular biology. Since 2001 Andreas has served as Managing Director of Ribopharma AG, Alnylam Europe AG and Roche Kulmbach GmbH. Prior to this he was the Managing Director of an IT company. Andreas has more than 25 years management experience and profound knowledge of finance and human resource.

Dr. Roland Kreutzer,

Managing Director

Roland was co-founder (2000) of Ribopharma AG (later Alnylam Europe AG and Roche Kulmbach GmbH). At Roche, he served as a member of the global research leadership team. He studied biology at the University Bayreuth, Germany. After completion of his Ph.D. in molecular genetics and research stays at the University of Sussex, UK, and the Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France, Roland did his postdoctoral lecture qualification (Habilitation) for biochemistry at the University of Bayreuth. He is co-inventor of pioneering fundamental patents in the field of RNAi.